Aurobindo Pharma share news, announcements and annual reports
NSE: AUROPHARMABSE: 524804Pharmaceuticals & BiotechnologyMid Cap
Aurobindo Pharma Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, Jul 2000 on NSE
Last close ₹1,681.40up ₹21.50 (1.30%)BSE ₹1,677.80
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,659.90.
30 Oct: open ₹1,652.00, high ₹1,687.00, low ₹1,647.20
52-week range of traded prices to 30 Oct 2026
₹1,091.20Low, 30 Oct 2025₹1,740.00High, 24 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results and dividend. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹96,744 Cr138th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.06
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.55
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 10.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.20
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 9,52,65057.5% delivered
Aurobindo Pharma board meetings
124 filed, newest first. Page 3 of 3.
Nov 2011
Oct 2011
31 Oct · Board meeting
To consider inter alia, the Un-audited Financial Results of the Company for the quarter and half year ended September 30, 2011.
Jul 2011
27 Jul · Board meeting
To consider inter alia, the Un-Audited Financial Results of the Company for the quarter ended June 30, 2011.
May 2011
9 May · Board meeting
Board of Directors of the Company at its Meeting held on May 09, 2011, has inter alia decided the following : In order to further strengthen and provide focus to the growing volume of APIs and Formulation Business, the Board has constituted a Re-structuring Committee to explore and evaluate possible growth linked restructuring options, inter alia, including spin-off or demerger or any other suitable form, with the ultimate objective of enhancing shareholders' value and customer satisfaction. The Restructuring Committee, consisting of directors including independent directors, will take all necessary steps and recommend the best options to the Board for consideration within a period of 3 months.
Apr 2011
29 Apr · Board meeting
Inter alia, to consider and approve the Audited Financial Results of the Company for the financial year ended March 31, 2011 and recommendation of final dividend, if any, for the financial year ended March 31, 2011.
Jan 2011
24 Jan · Board meeting
To consider inter alia, the Un-Audited Financial Results of the Company for the quarter ended December 31, 2010.
Oct 2010
21 Oct · Board meeting
To consider inter-alia, the Un-Audited Financial Results of the Company for the quarter and half year ended September 30, 2010.
Jul 2010
27 Jul · Board meeting
To consider inter-alia, the un-audited Financial Results of the Company for the quarter ended June 30, 2010.
May 2010
5 May · Board meeting
Inter alia, to consider and approve the Audited Financial Results of the Company for the financial year ended March 31, 2010 and recommendation of final dividend, if any, for the financial year ended March 31, 2010. In view of this, the Company will not be publishing the un-audited quarterly financial results of last quarter ending March 31, 2010.
Jan 2010
18 Jan · Board meeting
Meeting on 30 Jan 2010: “Unaudited Financial Results for the qtr ended Dec 31, 2009/Unaudited Financial Results/Dividend/Record date”
Nov 2009
9 Nov · Board meeting
To consider among other business, the Audited Annual Accounts of the Company for the year ended March 31, 2009 and also to recommend dividend, if any for the year ended March 31, 2009.
Oct 2009
20 Oct · Board meeting
To consider inter alia, the Un-audited Financial Results of the Company for the quarter and half year ended September 30, 2009.
Jul 2009
22 Jul · Board meeting
Meeting on 31 Jul 2009: “Unaudited Financial Results for the Qtr ended June 30, 2009”
Apr 2009
22 Apr · Board meeting
To consider inter alia, the Un-audited Financial Results of the company for the quarter and year ended March 31, 2009.
Mar 2009
27 Mar · Board meeting
To consider a Scheme of Arrangement.
Jan 2009
20 Jan · Board meeting
To consider among other business, the Un-audited Financial Results of the Company for the quarter ended December 31, 2008. The Board will also consider the proposal of payment of Interim Dividend for the year 2008-2009. Further, February 06, 2009 is being fixed as the Record date for the purpose of ascertaining the eligibility of shareholders for payment of Interim Dividend, if any, to be declared by the Board of Directors at the said meeting.
Oct 2008
22 Oct · Board meeting
To consider among other business, the Un-audited Financial Results of the Company for the quarter ended September 30, 2008.
Jul 2008
15 Jul · Board meeting
To consider among other business, the Un-audited Financial Results of the Company for the quarter ended June 30, 2008.
Jun 2008
5 Jun · Board meeting
To consider among other business, the Audited Financial Results of the Company for the Year ended March 31, 2008 and also to recommend Dividend, if any for the year ended March 31, 2008.
Jan 2008
17 Jan · Board meeting
To consider among other business, the Un-audited Financial Results of the Company for the quarter ended December 31, 2007.
Oct 2007
18 Oct · Board meeting
Meeting on 31 Oct 2007: “Unaudited Results for Qtr & Half year ended Sep 30, 2007”
Jul 2007
21 Jul · Board meeting
To consider among other business, the Un-audited Financial Results of the Company for the first quarter ended June 30, 2007.
Jun 2007
22 Jun · Board meeting
To consider among other business, the Audited Financial Results of the Company for the Year ended March 31, 2007 and also to recommend Dividend, if any for the year ended March 31, 2007.
Jan 2007
19 Jan · Board meeting
Meeting on 31 Jan 2007: “Unaudited Financial Results for the quarter ended Dec 31, 06”